Results 131 to 140 of about 13,388,827 (299)
Anti‐obesity medications and incident ocular outcomes: A systematic review and network meta‐analysis
VIEW, EarlyView.In this systematic review and network meta‑analysis of 140 studies, anti‑obesity medications showed heterogeneous ocular safety profiles. Semaglutide was associated with higher NAION risk (observational data), whereas dual/multi‑agonists and glucagon‐like peptide‐1 receptor agonists demonstrated favourable glaucoma and overall ocular outcomes ...
Linge Jian +5 more
wiley +1 more source
International Journal for Research Trends and Innovation, 2023 Purvita Laxman waghmodey +2 more
openaire +1 more source
Lactobacilli possess inhibitory activity against dipeptidyl peptidase-4 (DPP-4)
, 2015 Dipeptidyl peptidase 4 (DPP-4) enzymatically inactivates incretin hormones, and DPP-4 inhibitor drugs are clinically approved therapies for type 2 diabetes.
Panwar, Harsh +4 more
core +1 more source
The Journal of Dermatology, EarlyView.ABSTRACT Although population‐based studies have reported an increased risk of bullous pemphigoid and pemphigus associated with dipeptidyl peptidase‐4 (DPP‐4) inhibitors, there is limited, well‐designed epidemiological evidence for pemphigus vulgaris (PV), which has only been supported by case reports thus far.
Jaein Lee, Jae Hyun Bae, Seokyung Hahn
wiley +1 more source
Alogliptin benzoate for management of type 2 diabetes
Vascular Health and Risk Management, 2015 Yoshifumi Saisho Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan Abstract: Dipeptidyl peptidase-4 (DPP-4) inhibitors, a new class of oral hypoglycemic agents, augment glucose-dependent insulin secretion and suppress ...
Saisho Y
doaj
, 2014 Funnel plot for mean difference (MD) in the change in HbA1c (DPP-4 inhibitor vs. placebo or no treatment).
Dongsheng Cheng (652883) +6 more
core +1 more source
Andrology, EarlyView.ABSTRACT Background Drugs used for diabetes and obesity increasingly shape male sexual and reproductive counseling, but clinical studies, trial registrations, regulatory labels, and patents answer different questions. Objectives The objective is to map these sources and define what each can support when counseling men receiving metabolic drugs ...
Marek Broul +3 more
wiley +1 more source
Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus
, 2009 Type 2 diabetes mellitus (T2DM) is a global epidemic with increasing impact on individuals and healthcare providers. Available treatments (such as metformin, sulfonylureas, glitazones, and insulin) have proven unsatisfactory in producing a long-lasting ...
Piya, Milan K +10 more
core +1 more source
The Impact of Common Medications on Male Fertility: An Updated Systematic Review
Andrology, EarlyView.ABSTRACT Background Compared with those of cytotoxic treatments, the potential effects of common medications on the fertility of men trying to conceive currently or planning to conceive in the future are less well described. The use of common medications may modify the gonadotropic axis, spermatogenesis, and epididymal maturation or alter male ...
Lina Jebli +7 more
wiley +1 more source
Acta Ophthalmologica, EarlyView.Abstract Purpose To investigate the association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and nonarteritic anterior ischaemic optic neuropathy (NAION) in type 2 diabetes, examining treatment recency and cumulative duration. Methods This nationwide registry‐based nested case–control study utilizedz Danish health registries (1996 ...
Siar Niazi +9 more
wiley +1 more source